NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.
about
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imagingTherapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosisConsensus recommendations to accelerate clinical trials for neurofibromatosis type 2.Recommendations for imaging tumor response in neurofibromatosis clinical trials.Optimizing biologically targeted clinical trials for neurofibromatosis.Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies.Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform NeurofibromasUsing the neurofibromatosis tumor predisposition syndromes to understand normal nervous system development.Experiences of families with a child, adolescent, or young adult with neurofibromatosis type 1 and plexiform neurofibroma evaluated for clinical trials participation at the National Cancer Institute.Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas.Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.Clinical characteristics predicting internal neurofibromas in 357 children with neurofibromatosis-1: results from a cross-selectional study.Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1.MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I.Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.Neurogenic tumors of soft tissue.Neurofibromatosis type 1: diagnosis and recent advances.Pelvic neurofibroma arising from prostate in a case of neurofibromatosis-1.Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1.Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Multidisciplinary Recommendations for Care.Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas.Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.Therapeutics for childhood neurofibromatosis type 1 and type 2.Nutritional, muscular and metabolic characteristics in patients with neurofibromatosis type 1.Histopathologic Evaluation of Atypical Neurofibromatous Tumors and Their Transformation into Malignant Peripheral Nerve Sheath Tumor in Neurofibromatosis 1 Patients - A Consensus Overview.Growth behavior of plexiform neurofibromas after surgery.Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives.Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.The Characteristics of 76 Atypical Neurofibromas as Precursors to Neurofibromatosis 1 Associated Malignant Peripheral nerve Sheath Tumors.Characterization of spinal findings in children and adults with neurofibromatosis type 1 enrolled in a natural history study using magnetic resonance imaging.Anthropometric characteristics and comorbidities in Japanese patients with neurofibromatosis type 1: a single institutional case-control study.Interactive segmentation of plexiform neurofibroma tissue: method and preliminary performance evaluation.18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
P2860
Q28305337-730A448C-0AE7-439B-8ED8-23BF817FF626Q30357776-DEA59F50-F5D6-4360-8164-44A25D02942DQ30406342-4BA117DA-1A8B-4EA3-AABA-7FE6813B1F6CQ30425757-CED36735-E936-4193-9320-06D6B8BB9953Q30438898-58C02BB7-A8FF-450B-8CA9-EB75E0A4008DQ33737662-7F2313AB-6E59-4746-8F28-BB69EC1DD6D4Q33900906-5A9CDD94-07D3-43F0-9492-276921665D9EQ34176631-F3901451-67DE-4BB8-8C70-DEEABBB6FB6DQ34423849-D3028EA7-F260-4B4C-81AA-BC16E393CAE8Q34555308-5702ACB1-0A59-450A-BD39-A39C762C5433Q35788825-5323860C-90CB-4A1A-9110-0EA6E673A419Q35987649-7D6D3548-C20B-407D-B5F3-1E1F025EA8BEQ36369566-3B04CF2E-4DD1-4C25-AA84-AEE04B65743DQ36473944-164730DC-C543-41FB-957B-AB569C46372CQ36497139-DF1AAD57-E1D2-4681-962B-2462922F73ADQ37151995-7203062B-4822-4BE2-9484-EF7C805E8D11Q37393469-72BB530E-CE68-4C7B-A8B9-EF745345D974Q37620151-3716D409-D547-4169-A8AE-D88A8EABCB89Q37699439-69E42BC3-3711-4AAC-A52B-D085E415F3F1Q37737382-3DB2F383-4AD7-4CB3-9783-A3D5DD07323BQ37993923-B1135AC8-C70B-4EC2-BF25-5906864F5D74Q38089870-76420B41-C83C-4FC8-9278-BB75FD8AB2F0Q38710854-C67A549D-6330-47C8-87B9-05AD31C9B694Q38928315-C0D3D725-AD9E-4F5A-AE33-6027ECAEF5DDQ38928320-DB220DF4-4A3B-4B8B-AAF5-760AAD42A1F0Q39000307-E72BCB95-6676-4D5B-9254-E00E5FDFE4A7Q39502676-B663E71C-0536-48D1-8852-747F6816B1EBQ39555847-174C50F2-5E2A-4BB4-99D7-D88350E5346AQ39716494-FB31C521-05FE-4348-A44B-DEBA057A4D15Q40170626-60CEE560-FB3C-439F-AC3F-5387EC934C19Q40182996-F246954C-06C3-4CD8-8A80-2A0D27F8B328Q43851945-FE6CEA26-3A80-4891-898D-AB43A0158874Q47793357-822D7A38-2076-4BE9-A997-6791C7B6344FQ47872951-80F860DC-1147-4ECC-937B-E14A48F786FDQ48079152-E7426C9F-AD1F-4303-84AC-2183D3B59EFEQ48510261-A79BAFD8-A8B1-479F-8AA2-EA7EDA28EB6AQ50624919-D64251AA-B21F-4382-B0F6-DCD5FAB2746AQ51114860-86946C06-75BC-4705-A841-9E013D0A949FQ51353907-2722CBC5-F360-4E7B-9B15-15914638F22EQ53159228-5C78A06F-66F5-4DEE-BCC4-5355A7D3611D
P2860
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
NF1 plexiform neurofibroma gro ...... onship to age and body weight.
@en
NF1 plexiform neurofibroma gro ...... onship to age and body weight.
@nl
type
label
NF1 plexiform neurofibroma gro ...... onship to age and body weight.
@en
NF1 plexiform neurofibroma gro ...... onship to age and body weight.
@nl
prefLabel
NF1 plexiform neurofibroma gro ...... onship to age and body weight.
@en
NF1 plexiform neurofibroma gro ...... onship to age and body weight.
@nl
P2093
P1433
P1476
NF1 plexiform neurofibroma gro ...... ionship to age and body weight
@en
P2093
A J Gillespie
B C Widemann
D Babovic-Vuksanovic
N Patronas
R J Packer
P304
P356
10.1212/01.WNL.0000250332.89420.E6
P407
P577
2007-01-10T00:00:00Z